Article
Evaluation of the predictive value of Her-2/neu overexpression and p53 mutations in high-risk primary breast cancer patients treated with high-dose chemotherapy and autologous stem-cell transplantation.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology - 1 May 2000
Nieto Y, Cagnoni P J, Nawaz S, Shpall E J, Yerushalmi R, Cook B, Russell P, McDermit J, Murphy J, Bearman S I, Jones R B
Abstract excerpt
PURPOSE: To ascertain the predictive value of Her-2/neu overexpression and p53 mutations, assessed by immunohistochemistry, in high-risk primary breast cancer (HRPBC) treated with high-dose chemotherapy (HDCT). PATIENTS AND METHODS: We obtained paraffin-embedded tumor blocks from 146 HRPBC patients previously enrolled at our program onto clinical trials of HDCT for four to nine involved axillary lymph nodes, > or...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.